Prakt. lékáren. 2012; 8(2): 62-65
Treatment of obesity in patiens with diabetes mellitus: part two
- Městská nemocnice Neratovice
In the first part of the article, there were described the importance of obesity as a risk factor for many serious diseases, different methods of
investigation of obese patients and their treatment by lifestyle changes – diet and exercise. The second part deals with other methods of treatment
– pharmacotherapy, surgical therapy and psychotherapy. Also the influence of antidiabetic therapy on patient weight is mentioned.
Keywords: overweight and obesity, antidiabetics, surgical treatment, cognitive-behavioral approach
Published: April 23, 2012 Show citation
References
- Buchwald H, Estok R, Fahrbach K, Banel D, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122(3): 248-256.
Go to original source... 
Go to PubMed... - Buse JB, Rosenstock J, Sesti G, Schmid WE, Montanya E, et al. for the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47. Go to original source... Go to PubMed...
- DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprabdial glukose, insulin and glucagon secretion, Bystric emptying and caloric intake: a randomized, Gross-over study. Curr Med Res Opin 2008; 24: 2943-2952. Go to original source... Go to PubMed...
- Dormandy JA, Charbonnel B, Eckland EJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet 2005; 366: 1279-1289. Go to original source... Go to PubMed...
- Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care 2011; 34(6): 1424-1430. Epub 2011 May 20. Go to original source... Go to PubMed...
- Fried M, Ribaric G, Buchwald JN, Svacina S, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI < 35 kg/m2: an integrative review of early studies. Obes Surg 2010; 20(6): 776-790. Go to original source... Go to PubMed...
- Golay A. Metformin and body weight. International Journal of Obesity 2008; 32: 61-72. Go to original source... Go to PubMed...
- Home PD, Pocock SJ, Beck-Nielse H, Curtis P, Gomis R, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135. Go to original source... Go to PubMed...
- Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glukose-lowering agent? Expert Opin. Investig. Drugs 2010; 19(12): 1581-1589. Go to original source... Go to PubMed...
- Pratley R, Nauck M, Bailey T, Montanya E, et al. One year of liraglitide treatment offers sustained and more effective glycaemic kontrol and weight reduction compared with sitagliptin, both in combination with metformin, in patiens with type 2 diabetes: a randomised, paralel-group, open-label trial. Int J Clin Pract 2011; 65: 397-407. Go to original source... Go to PubMed...
- Tailor K, Guiney K, Han J, Pencek R, et al. Exenatide once weekly treatment maintained improvements in glycemic kontrol and weight loss over 2 years. BMC Endocrine Disorders 2011; 11: 9. http://www.biomedcentral.com/1472-6823/11/9. Go to original source... Go to PubMed...
- Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes, Obesity and Metabolism 2010; 12: 510-516. Go to original source... Go to PubMed...